A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)

NCT00096954 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

333

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: omalizumab (Xolair)
DRUG: placebo

Sponsor

Genentech, Inc.